Education, Counseling, and Drug Therapy to Reduce Symptoms of Metabolic Syndrome
NCT ID: NCT00129792
Last Updated: 2014-10-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
79 participants
INTERVENTIONAL
2005-01-31
2014-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Precision Nutrition and Metabolic Function
NCT04131166
Effects of Low and Moderate Fat Diets on Lipids, Inflammation and Vascular Reactivity in the Metabolic Syndrome
NCT00362908
Complex Effects of Dietary Manipulation on Metabolic Function, Inflammation and Health
NCT02706262
Dietary Interventions in Prediabetes
NCT01729078
Effects of Macronutrients on Hepatic Lipids, Plasma Triglycerides, and Insulin Sensitivity
NCT00523562
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This study will last 12 weeks. Participants will be randomly assigned to one of three arms. Participants in Arm 1 will receive the supplement; participants in Arm 2 will have a 50% chance of receiving either the supplement or placebo; participants in Arm 3 will receive placebo. Participants will take their assigned pills 3 times daily for 12 weeks. A follow-up visit will occur at the end of the 12 weeks; there will be a debriefing visit shortly after the follow-up visit. Participants in all 3 arms will receive weekly education and counseling sessions on healthy lifestyle changes to encourage weight loss. Blood collection will occur at study start and at the end of 12 weeks for assessment of fasting blood glucose, insulin, cholesterol, and levels of certain hormones. Participants will also be asked to complete questionnaires at study entry and at Week 12; the questionnaires will assess depression, stress, self-absorption, optimism, food cravings, hunger, the degree to which participants seek pleasure from activities, and participants' thoughts about their ability to make behavioral changes.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Has 100% expectation of receiving supplement
Dietary supplement for weight loss
The dietary supplement being investigated in this study is a natural product designed to reduce metabolic syndrome by decreasing hunger, increasing energy, and improving insulin function.
Education and counseling for weight loss
Hour and a half weight loss education session weekly for 12 weeks.
2
Has 50% expectation of receiving supplement
Dietary supplement for weight loss
The dietary supplement being investigated in this study is a natural product designed to reduce metabolic syndrome by decreasing hunger, increasing energy, and improving insulin function.
Education and counseling for weight loss
Hour and a half weight loss education session weekly for 12 weeks.
3
Has 0% expectation of receiving supplement.
Education and counseling for weight loss
Hour and a half weight loss education session weekly for 12 weeks.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Dietary supplement for weight loss
The dietary supplement being investigated in this study is a natural product designed to reduce metabolic syndrome by decreasing hunger, increasing energy, and improving insulin function.
Education and counseling for weight loss
Hour and a half weight loss education session weekly for 12 weeks.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Live in the Portland, Oregon metropolitan area
* Willing and able to complete a 12-week weight loss program
* Meet at least 3 of the following 5 criteria: 1) waist circumference greater than 40 inches for men and 35 inches for women; 2) fasting triglycerides higher than 150 mg/dl; 3) high density lipoprotein (HDL) lower than 40 mg/dl for men and 50 mg/dl for women; 4) systolic blood pressure (BP) of 130 mmHg or higher or diastolic BP of 85 mmHg or higher; 5) fasting glucose of 100 mg/dl or higher
Exclusion Criteria
* Medical conditions contraindicating a diet and exercise weight loss program
* History of congestive heart failure, stroke, myocardial infarction, coronary artery bypass graft, or atherosclerotic cardiovascular disease
* Current diagnosis of cancer
* Hospitalization for a psychiatric condition within 12 months prior to study entry
* Weight loss medications within 6 months prior to study entry
* Change in body weight greater than 5% within 6 months prior to study entry
* Consumption of more than 21 alcoholic drinks per week
* Current participation in another clinical trial OR living in the same household with another participant in this study
* Currently exercising for more than 30 minutes, 3 times per week
* Fasting blood glucose higher than 125 mg/dl
* BP higher than 145/90
* Triglycerides higher than 500 mg/dl
* Training as a health care provider or health scientist
* Pregnancy or breastfeeding
21 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Center for Complementary and Integrative Health (NCCIH)
NIH
Oregon Health and Science University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Barry S. Oken
MD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Barry Oken, MD
Role: PRINCIPAL_INVESTIGATOR
Oregon Health and Science University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Oregon Health and Science University General Clinical Research Center
Portland, Oregon, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.